Third Harmonic Bio Key Executives
This section highlights Third Harmonic Bio's key executives, including their titles and compensation details.
Find Contacts at Third Harmonic Bio
(Showing 0 of )
Third Harmonic Bio Earnings
This section highlights Third Harmonic Bio's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for Third Harmonic Bio, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $35.00K | $38.00K | $- | $- |
| Gross Profit | $- | $-35.00K | $-38.00K | $- | $- |
| Gross Profit Ratio | 0.00% | - | - | 0.00% | 0.00% |
| Research and Development Expenses | $36.50M | $23.96M | $24.41M | $15.75M | $9.95M |
| General and Administrative Expenses | $22.37M | $19.99M | $13.30M | $3.26M | $1.17M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $22.37M | $19.99M | $13.30M | $3.26M | $1.17M |
| Other Expenses | $- | $- | $2.55M | $-10.61M | $-1.69M |
| Operating Expenses | $58.87M | $43.92M | $37.71M | $19.00M | $11.12M |
| Cost and Expenses | $- | $43.95M | $37.71M | $19.00M | $11.12M |
| Interest Income | $-13.41M | $13.13M | $2.55K | $5 | $- |
| Interest Expense | $- | $- | $2.55M | $- | $- |
| Depreciation and Amortization | $- | $35.00K | $38.00K | $19.00M | $11.12M |
| EBITDA | $58.87M | $-30.79M | $-35.12M | $-10.61M | $-1.69M |
| EBITDA Ratio | - | - | - | - | - |
| Operating Income | $58.87M | $-43.95M | $-37.71M | $-19.00M | $-11.12M |
| Operating Income Ratio | - | - | - | - | - |
| Total Other Income Expenses Net | $-13.40M | $13.13M | $2.55M | $-10.61M | $-1.69M |
| Income Before Tax | $45.47M | $-30.82M | $-35.16M | $-29.61M | $-12.81M |
| Income Before Tax Ratio | - | - | - | - | - |
| Income Tax Expense | $- | $- | $2.55M | $-19.00K | $-1.00K |
| Net Income | $45.47M | $-30.82M | $-37.71M | $-29.61M | $-12.81M |
| Net Income Ratio | - | - | - | - | - |
| EPS | $1.09 | $-0.78 | $-0.96 | $-0.77 | $-0.33 |
| EPS Diluted | $1.09 | $-0.78 | $-0.96 | $-0.77 | $-0.33 |
| Weighted Average Shares Outstanding | 41.73M | 39.65M | 39.38M | 38.69M | 38.69M |
| Weighted Average Shares Outstanding Diluted | 41.73M | 39.65M | 39.38M | 38.69M | 38.69M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $836.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $12.00K | $12.00K | $13.00K | $178.00K | $168.00K | $- | $38.00K | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $- | $- | $-12.00K | $-12.00K | $823.00K | $-178.00K | $-168.00K | $- | $-38.00K | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | - | 0.00% | - | - | 98.44% | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $10.54M | $11.34M | $8.39M | $6.23M | $5.92M | $5.97M | $5.34M | $6.74M | $9.26M | $4.76M | $4.18M | $6.21M | $4.29M | $4.92M | $3.27M | $3.27M |
| General and Administrative Expenses | $5.90M | $5.73M | $5.68M | $5.06M | $4.49M | $4.88M | $5.37M | $5.25M | $4.29M | $3.83M | $3.60M | $1.57M | $1.47M | $780.00K | $505.00K | $505.00K |
| Selling and Marketing Expenses | $- | $- | $-12.00K | $-12.00K | $-13.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $5.90M | $5.73M | $5.66M | $5.05M | $4.47M | $4.88M | $5.37M | $5.25M | $4.29M | $3.83M | $3.60M | $1.57M | $1.47M | $780.00K | $505.00K | $505.00K |
| Other Expenses | $- | $- | $-1.00K | $1.00K | $-6.00K | $34.00K | $-4.00K | $- | $2.06M | $383.00K | $107.00K | $3.00K | $-10.03M | $-1.68M | $- | $- |
| Operating Expenses | $16.44M | $17.07M | $14.06M | $11.28M | $10.39M | $10.85M | $10.71M | $11.99M | $13.55M | $8.59M | $7.78M | $7.79M | $5.75M | $5.70M | $3.22M | $3.22M |
| Cost and Expenses | $16.44M | $17.07M | $14.07M | $11.29M | $10.40M | $10.85M | $10.71M | $11.99M | $13.55M | $8.59M | $7.78M | $7.79M | $5.75M | $5.70M | $3.22M | $3.22M |
| Interest Income | $3.33M | $3.28M | $3.36M | $3.43M | $3.58M | $3.47M | $3.16M | $2.90M | $2.55K | $383.00K | $107.00K | $- | $- | $- | $1.00K | $1.00K |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $- | $2.17M | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $13.00K | $12.00K | $12.00K | $12.00K | $13.00K | $178.00K | $168.00K | $3.00K | $38.00K | $8.59M | $7.78M | $7.79M | $5.75M | $5.70M | $3.78M | $3.78M |
| EBITDA | $-16.43M | $-17.06M | $-10.70M | $-11.28M | $-10.39M | $-10.84M | $-10.71M | $-11.98M | $-13.55M | $-8.21M | $107.00K | $3.00K | $-5.75M | $-1.68M | $555.00K | $555.00K |
| EBITDA Ratio | - | - | - | - | -1243.06% | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | $-16.44M | $-17.07M | $-14.07M | $-11.29M | $-10.40M | $10.85M | $-10.71M | $-11.99M | $-13.55M | $-8.59M | $-7.78M | $-7.79M | $-5.75M | $-5.70M | $-3.78M | $-3.78M |
| Operating Income Ratio | - | - | - | - | -1244.62% | - | - | - | - | - | - | - | - | - | - | - |
| Total Other Income Expenses Net | $3.33M | $3.27M | $3.36M | $3.43M | $3.57M | $3.50M | $3.15M | $2.90M | $2.06M | $383.00K | $107.00K | $3.00K | $-10.03M | $-1.68M | $555.00K | $555.00K |
| Income Before Tax | $-13.11M | $-13.80M | $-10.71M | $-7.86M | $-6.84M | $7.34M | $-7.56M | $-9.09M | $-11.49M | $-8.21M | $-7.68M | $-7.78M | $-15.78M | $-7.38M | $-3.22M | $-3.22M |
| Income Before Tax Ratio | - | - | - | - | -817.70% | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax Expense | $- | $- | $- | $-31.28K | $267.00K | $-12.00K | $-3.16M | $- | $2.17M | $-8.59M | $-107.00K | $-3.00K | $-5.75M | $-5.70M | $555.00K | $555.00K |
| Net Income | $-13.11M | $-13.80M | $-10.71M | $-7.86M | $-6.84M | $7.34M | $-7.56M | $-9.09M | $-13.66M | $-8.21M | $-7.57M | $-7.78M | $-15.78M | $-7.38M | $-3.22M | $-3.22M |
| Net Income Ratio | - | - | - | - | -817.70% | - | - | - | - | - | - | - | - | - | - | - |
| EPS | $0.33 | $0.33 | $-0.26 | $-0.20 | $-0.17 | $0.19 | $-0.19 | $-0.23 | $-0.35 | $-0.90 | $-0.20 | $-0.30 | $-0.60 | $-0.28 | $-0.82 | $-0.82 |
| EPS Diluted | $0.33 | $0.33 | $-0.26 | $-0.20 | $-0.17 | $0.19 | $-0.19 | $-0.23 | $-0.35 | $-0.90 | $-0.20 | $-0.30 | $-0.60 | $-0.28 | $-0.82 | $-0.82 |
| Weighted Average Shares Outstanding | 41.32M | 41.32M | 40.56M | 40.21M | 39.92M | 39.69M | 39.57M | 39.44M | 39.38M | 9.12M | 38.69M | 26.29M | 26.29M | 26.29M | 3.94M | 3.94M |
| Weighted Average Shares Outstanding Diluted | 41.32M | 41.32M | 40.56M | 40.21M | 39.92M | 39.69M | 39.57M | 39.44M | 39.38M | 9.12M | 38.69M | 26.29M | 26.29M | 26.29M | 3.94M | 3.94M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $285.06M | $269.07M | $288.88M | $128.28M | $8.28M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $285.06M | $269.07M | $288.88M | $128.28M | $8.28M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $5.47M | $3.38M | $3.96M | $884.00K | $312.00K |
| Total Current Assets | $290.54M | $272.45M | $292.83M | $129.16M | $8.43M |
| Property Plant Equipment Net | $3.17M | $3.93M | $4.36M | $- | $- |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $441.00K | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $901.00K | $1.33M | $1.04M | $- | $- |
| Total Non-Current Assets | $4.07M | $5.26M | $5.84M | $- | $- |
| Other Assets | $- | $- | $-0 | $- | $- |
| Total Assets | $294.61M | $277.71M | $298.68M | $129.16M | $8.43M |
| Account Payables | $1.94M | $1.84M | $2.09M | $1.80M | $581.00K |
| Short Term Debt | $859.00K | $745.00K | $770.00K | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $4.31M | $2.83M | $2.80M | $3.89M | $1.63M |
| Total Current Liabilities | $7.11M | $5.42M | $5.65M | $5.69M | $2.21M |
| Long Term Debt | $2.35M | $3.21M | $7.91M | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $-3.95M | $- | $24.58M |
| Total Non-Current Liabilities | $2.35M | $3.21M | $3.95M | $170.18M | $24.58M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $9.46M | $8.63M | $9.61M | $175.87M | $26.79M |
| Preferred Stock | $- | $- | $298.68M | $170.18M | $18.70M |
| Common Stock | $5.00K | $4.00K | $4.00K | $1.00K | $1.00K |
| Retained Earnings | $-159.69M | $-114.22M | $-83.40M | $-48.24M | $-18.63M |
| Accumulated Other Comprehensive Income Loss | $- | $-0 | $-0 | $-170.18M | $-18.70M |
| Other Total Stockholders Equity | $444.83M | $383.30M | $372.46M | $340.37M | $37.40M |
| Total Stockholders Equity | $285.15M | $269.08M | $289.07M | $-46.71M | $-18.36M |
| Total Equity | $285.15M | $269.08M | $289.07M | $-46.71M | $-18.36M |
| Total Liabilities and Stockholders Equity | $294.61M | $277.71M | $298.68M | $129.16M | $8.43M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $294.61M | $277.71M | $298.68M | $129.16M | $8.43M |
| Total Investments | $- | $453.00K | $441.00K | $- | $- |
| Total Debt | $3.21M | $3.95M | $4.34M | $- | $- |
| Net Debt | $-281.86M | $-265.12M | $-284.54M | $-128.28M | $-8.28M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $285.06M | $296.09M | $255.33M | $262.83M | $269.07M | $273.89M | $278.13M | $282.20M | $288.88M | $299.52M | $112.73M | $-128.28M | $128.28M | $-8.28M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $256.56M | $- | $16.55M |
| Cash and Short Term Investments | $285.06M | $296.09M | $255.33M | $262.83M | $269.07M | $273.89M | $278.13M | $282.20M | $288.88M | $299.52M | $112.73M | $128.28M | $128.28M | $8.28M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $5.47M | $4.14M | $5.90M | $2.77M | $3.38M | $2.84M | $2.23M | $3.54M | $3.96M | $8.11M | $610.00K | $- | $884.00K | $- |
| Total Current Assets | $290.54M | $300.23M | $261.23M | $265.60M | $272.45M | $276.73M | $280.37M | $285.75M | $292.83M | $303.57M | $113.34M | $128.28M | $129.16M | $8.28M |
| Property Plant Equipment Net | $3.17M | $3.36M | $3.56M | $3.75M | $3.93M | $4.11M | $4.29M | $4.32M | $4.36M | $- | $- | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $453.00K | $453.00K | $453.00K | $441.00K | $441.00K | $- | $441.00K | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $901.00K | $902.00K | $620.00K | $725.00K | $880.00K | $968.00K | $726.00K | $1.32M | $1.04M | $1.19M | $1.09M | $-128.28M | $- | $-8.28M |
| Total Non-Current Assets | $4.07M | $4.26M | $4.63M | $4.92M | $5.26M | $5.52M | $5.46M | $5.64M | $5.84M | $1.19M | $1.09M | $-128.28M | $- | $-8.28M |
| Other Assets | $- | $- | $1 | $1 | $1 | $- | $- | $- | $-0 | $- | $- | $- | $- | $- |
| Total Assets | $294.61M | $304.49M | $265.86M | $270.52M | $277.71M | $282.25M | $285.82M | $291.39M | $298.68M | $304.76M | $114.43M | $- | $129.16M | $- |
| Account Payables | $1.94M | $2.86M | $1.44M | $945.00K | $1.84M | $1.97M | $1.34M | $2.67M | $2.09M | $3.34M | $2.44M | $- | $1.80M | $- |
| Short Term Debt | $859.00K | $829.00K | $1.60M | $773.00K | $1.49M | $1.44M | $1.39M | $668.00K | $770.00K | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $3.18M | $2.06M | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $4.31M | $3.38M | $3.31M | $2.30M | $2.09M | $2.48M | $1.49M | $1.61M | $2.80M | $3.00M | $2.37M | $- | $3.89M | $- |
| Total Current Liabilities | $7.11M | $7.07M | $6.35M | $4.02M | $5.42M | $5.89M | $4.22M | $4.95M | $5.65M | $6.34M | $4.80M | $- | $5.69M | $- |
| Long Term Debt | $2.35M | $2.57M | $2.79M | $3.00M | $6.42M | $6.81M | $7.18M | $3.77M | $7.91M | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $-3.21M | $-3.40M | $-3.59M | $- | $-3.95M | $- | $170.18M | $- | $170.18M | $- |
| Total Non-Current Liabilities | $2.35M | $2.57M | $2.79M | $3.00M | $3.21M | $3.40M | $3.59M | $3.77M | $3.95M | $- | $170.18M | $- | $170.18M | $- |
| Other Liabilities | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $9.46M | $9.64M | $9.14M | $7.02M | $8.63M | $9.29M | $7.81M | $8.72M | $9.61M | $6.34M | $174.99M | $- | $175.87M | $- |
| Preferred Stock | $- | $- | $- | $0 | $- | $- | $- | $- | $- | $- | $170.18K | $170.18M | $170.18M | $18.70M |
| Common Stock | $5.00K | $5.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $1.00K | $- | $1.00K | $- |
| Retained Earnings | $-159.69M | $-146.58M | $-132.78M | $-122.08M | $-114.22M | $-107.38M | $-100.04M | $-92.48M | $-83.40M | $-71.91M | $-63.70M | $- | $-48.24M | $- |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $-0 | $-0 | $-0 | $-0 | $- | $-0 | $- | $-170.18K | $-46.71M | $-170.18M | $-18.36M |
| Other Total Stockholders Equity | $444.83M | $441.43M | $389.49M | $385.57M | $383.30M | $380.34M | $378.05M | $375.14M | $372.46M | $370.32M | $3.14M | $- | $-168.65M | $- |
| Total Stockholders Equity | $285.15M | $294.85M | $256.71M | $263.50M | $269.08M | $272.96M | $278.01M | $282.67M | $289.07M | $298.42M | $-60.56M | $123.48M | $-46.71M | $342.00K |
| Total Equity | $285.15M | $294.85M | $256.71M | $263.50M | $269.08M | $272.96M | $278.01M | $282.67M | $289.07M | $298.42M | $-60.56M | $123.48M | $-46.71M | $342.00K |
| Total Liabilities and Stockholders Equity | $294.61M | $304.49M | $265.86M | $270.52M | $277.71M | $282.25M | $285.82M | $291.39M | $298.68M | $304.76M | $114.43M | $123.48M | $129.16M | $342.00K |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $294.61M | $304.49M | $265.86M | $270.52M | $277.71M | $282.25M | $285.82M | $291.39M | $298.68M | $304.76M | $114.43M | $123.48M | $129.16M | $342.00K |
| Total Investments | $- | $- | $453.00K | $453.00K | $453.00K | $441.00K | $441.00K | $- | $441.00K | $- | $- | $256.56M | $- | $16.55M |
| Total Debt | $3.21M | $3.40M | $3.59M | $3.77M | $3.95M | $4.12M | $4.28M | $4.44M | $4.34M | $- | $- | $- | $- | $- |
| Net Debt | $-281.86M | $-292.69M | $-251.74M | $-259.05M | $-265.12M | $-269.77M | $-273.85M | $-277.76M | $-284.54M | $-299.52M | $-112.73M | $128.28M | $-128.28M | $8.28M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-45.47M | $-30.82M | $-35.16M | $-29.61M | $-12.81M |
| Depreciation and Amortization | $49.00K | $35.00K | $1.00K | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $11.09M | $9.58M | $4.75M | $510.00K | $195.00K |
| Change in Working Capital | $-893.00K | $223.00K | $-4.55M | $2.74M | $1.74M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $99.00K | $-249.00K | $290.00K | $1.22M | $324.00K |
| Other Working Capital | $-992.00K | $472.00K | $-4.84M | $1.53M | $1.41M |
| Other Non Cash Items | $724.00K | $564.00K | $37.00K | $10.61M | $1.69M |
| Net Cash Provided by Operating Activities | $-34.50M | $-20.43M | $-34.92M | $-15.75M | $-9.19M |
| Investments in Property Plant and Equipment | $-10.00K | $-169.00K | $-36.00K | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-10.00K | $-169.00K | $-36.00K | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $48.67M | $799.00K | $198.18M | $135.75M | $10.82M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.84M | $799.00K | $-2.19M | $135.75M | $10.82M |
| Net Cash Used Provided by Financing Activities | $50.51M | $799.00K | $195.99M | $135.75M | $10.82M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $15.99M | $-19.80M | $161.04M | $120.00M | $1.64M |
| Cash at End of Period | $285.52M | $269.52M | $289.32M | $128.28M | $8.28M |
| Cash at Beginning of Period | $269.52M | $289.32M | $128.28M | $8.28M | $6.64M |
| Operating Cash Flow | $-34.50M | $-20.43M | $-34.92M | $-15.75M | $-9.19M |
| Capital Expenditure | $-10.00K | $-169.00K | $-36.00K | $- | $- |
| Free Cash Flow | $-34.51M | $-20.59M | $-34.95M | $-15.75M | $-9.19M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-13.11M | $-13.80M | $-10.71M | $-7.86M | $-6.84M | $-7.34M | $-7.56M | $-9.09M | $-11.49M | $-8.21M | $-7.68M | $-7.78M | $-15.78M | $-7.38M | $-3.22M | $-3.22M |
| Depreciation and Amortization | $13.00K | $12.00K | $12.00K | $12.00K | $13.00K | $12.00K | $7.00K | $3.00K | $1.00K | $- | $- | $- | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $-1.89M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $3.19M | $3.06M | $2.61M | $2.22M | $1.76M | $2.29M | $2.85M | $2.68M | $2.13M | $1.01M | $1.16M | $450.00K | $235.00K | $137.00K | $69.00K | $69.00K |
| Change in Working Capital | $-1.52M | $1.75M | $-899.00K | $-846.00K | $-711.00K | $691.00K | $587.00K | $-344.00K | $32.00K | $-3.58M | $-222.00K | $-779.00K | $1.17M | $1.41M | $-360.00K | $-360.00K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-920.00K | $1.42M | $494.00K | $-893.00K | $-108.00K | $603.00K | $-1.31M | $571.00K | $-914.00K | $839.00K | $567.00K | $-202.00K | $476.00K | $-145.00K | $- | $- |
| Other Working Capital | $-596.00K | $327.00K | $-1.39M | $47.00K | $-603.00K | $88.00K | $1.90M | $-915.00K | $946.00K | $-4.42M | $-789.00K | $-577.00K | $697.00K | $1.55M | $-360.00K | $-360.00K |
| Other Non Cash Items | $187.00K | $807.00K | $2.32M | $3.31M | $2.06M | $166.00K | $161.00K | $69.00K | $37.00K | $842.00K | $567 | $-202.00K | $10.03M | $1.69M | $-111.50K | $-111.50K |
| Net Cash Provided by Operating Activities | $-11.23M | $-8.17M | $-8.81M | $-6.29M | $-5.61M | $-4.18M | $-3.96M | $-6.67M | $-9.29M | $-10.78M | $-6.74M | $-8.11M | $-4.34M | $-4.15M | $-3.63M | $-3.63M |
| Investments in Property Plant and Equipment | $-10.00K | $- | $- | $- | $-1.00K | $- | $-168.00K | $- | $-36.00K | $- | $- | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-10.00K | $- | $- | $- | $-1.00K | $- | $-168.00K | $- | $-36.00K | $- | $- | $- | $- | $- | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $47.31M | $1.31M | $49.00K | $798.00K | $-57.00K | $58.00K | $- | $198.18M | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $210.00K | $48.94M | $1.31M | $49.00K | $798.00K | $-57.00K | $58.00K | $- | $-875.00K | $197.56M | $-697.00K | $- | $119.83M | $1.00K | $7.96M | $7.96M |
| Net Cash Used Provided by Financing Activities | $210.00K | $48.94M | $1.31M | $49.00K | $798.00K | $-57.00K | $58.00K | $- | $-875.00K | $197.56M | $-697.00K | $- | $119.83M | $1.00K | $7.96M | $7.96M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-12.00K | $- | $11.63M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-11.03M | $40.76M | $-7.50M | $-6.24M | $-4.82M | $-4.24M | $-4.07M | $-6.67M | $-10.20M | $186.78M | $-7.44M | $-8.11M | $115.49M | $-4.15M | $4.33M | $4.33M |
| Cash at End of Period | $285.52M | $296.55M | $255.33M | $262.83M | $269.07M | $274.33M | $278.57M | $282.64M | $289.32M | $299.52M | $112.73M | $120.17M | $128.28M | $12.79M | $16.95M | $4.33M |
| Cash at Beginning of Period | $296.55M | $255.78M | $262.83M | $269.07M | $273.89M | $278.57M | $282.64M | $289.32M | $299.52M | $112.73M | $120.17M | $128.28M | $12.79M | $16.95M | $12.61M | $- |
| Operating Cash Flow | $-11.23M | $-8.17M | $-8.81M | $-6.29M | $-5.61M | $-4.18M | $-3.96M | $-6.67M | $-9.29M | $-10.78M | $-6.74M | $-8.11M | $-4.34M | $-4.15M | $-3.63M | $-3.63M |
| Capital Expenditure | $-10.00K | $- | $- | $- | $-1.00K | $- | $-168.00K | $- | $-36.00K | $- | $- | $- | $- | $- | $- | $- |
| Free Cash Flow | $-11.24M | $-8.17M | $-8.81M | $-6.29M | $-5.61M | $-4.18M | $-4.13M | $-6.67M | $-9.32M | $-10.78M | $-6.74M | $-8.11M | $-4.34M | $-4.15M | $-3.63M | $-3.63M |
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
$5.15
Stock Price
$232.31M
Market Cap
53
Employees
Cambridge, MA
Location
Revenue (FY 2024)
$-
0.0% YoY
Net Income (FY 2024)
$45.47M
247.5% YoY
EPS (FY 2024)
$1.09
239.7% YoY
Free Cash Flow (FY 2024)
$-34.51M
-67.6% YoY
Profitability
Gross Margin
0.0%
Net Margin
0.0%
ROE
15.9%
ROA
15.4%
Valuation
P/E Ratio
9.44
P/S Ratio
0.00
EV/EBITDA
2.51
Market Cap
$232.31M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-34.50M
-68.9% YoY
Free Cash Flow
$-34.51M
-67.6% YoY
Balance Sheet Summary
Total Assets
$294.61M
6.1% YoY
Total Debt
$3.21M
18.8% YoY
Shareholder Equity
$285.15M
0.7% YoY
Dividend Overview
$0.12
Latest Dividend
%
Dividend Yield
%
Payout Ratio
Recent Dividend History
| Date | Amount | Type |
|---|---|---|
| 2014-08-06 | $0.12 | August 06, 14 |
| 2014-05-06 | $0.12 | May 06, 14 |
| 2014-02-05 | $0.12 | February 05, 14 |
| 2013-11-06 | $0.10 | November 06, 13 |
| 2013-08-06 | $0.10 | August 06, 13 |
| 2013-05-06 | $0.05 | May 06, 13 |
| 2013-02-06 | $0.05 | February 06, 13 |
| 2012-11-06 | $0.05 | November 06, 12 |
| 2012-08-06 | $0.05 | August 06, 12 |
| 2012-05-04 | $0.05 | May 04, 12 |
Third Harmonic Bio Dividends
Explore Third Harmonic Bio's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
-3450.30x
Third Harmonic Bio Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.12 | $0.12 | August 06, 2014 | August 08, 2014 | August 15, 2014 | July 30, 2014 |
| $0.12 | $0.12 | May 06, 2014 | May 08, 2014 | May 15, 2014 | April 24, 2014 |
| $0.12 | $0.12 | February 05, 2014 | February 07, 2014 | February 14, 2014 | January 27, 2014 |
| $0.1 | $0.1 | November 06, 2013 | November 08, 2013 | November 15, 2013 | October 24, 2013 |
| $0.1 | $0.1 | August 06, 2013 | August 08, 2013 | August 15, 2013 | July 25, 2013 |
| $0.05 | $0.05 | May 06, 2013 | May 08, 2013 | May 15, 2013 | April 25, 2013 |
| $0.05 | $0.05 | February 06, 2013 | February 08, 2013 | February 15, 2013 | January 24, 2013 |
| $0.05 | $0.05 | November 06, 2012 | November 15, 2012 | October 25, 2012 | |
| $0.05 | $0.05 | August 06, 2012 | August 15, 2012 | July 26, 2012 | |
| $0.05 | $0.05 | May 04, 2012 | May 15, 2012 | April 27, 2012 | |
| $0.05 | $0.05 | February 06, 2012 | February 15, 2012 | January 26, 2012 | |
| $0.05 | $0.05 | November 04, 2011 | November 15, 2011 | October 27, 2011 | |
| $0.05 | $0.05 | August 04, 2011 | August 15, 2011 | July 29, 2011 | |
| $0.05 | $0.05 | May 05, 2011 | May 16, 2011 | April 28, 2011 | |
| $0.05 | $0.05 | February 04, 2011 | February 15, 2011 | January 31, 2011 | |
| $0.2 | $0.2 | November 04, 2010 | November 15, 2010 | October 28, 2010 | |
| $0.2 | $0.2 | August 05, 2010 | August 16, 2010 | July 29, 2010 | |
| $0.2 | $0.2 | May 06, 2010 | May 14, 2010 | April 29, 2010 | |
| $0.2 | $0.2 | February 05, 2010 | February 16, 2010 | January 28, 2010 | |
| $0.2 | $0.2 | November 05, 2009 | November 16, 2009 | October 29, 2009 |
Third Harmonic Bio News
Read the latest news about Third Harmonic Bio, including recent articles, headlines, and updates.
Third Harmonic Bio, Inc. (THRD) Loses -31.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Third Harmonic Bio, Inc. (THRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD)
The heavy selling pressure might have exhausted for Third Harmonic Bio, Inc. (THRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update
THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value Cash and cash equivalents of approximately $285 million as of December 31, 2024 (unaudited) Management to hold conference call/webcast today Tuesday, February 11, 2025, at 8:00 a.m. EST to discuss clinical results and corporate next steps SAN FRANCISCO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced results from its Phase 1 single and multiple ascending dose (SAD/MAD) clinical trial of THB335 in healthy volunteers.
Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chris Murphy, Chief Financial and Business Officer, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Wednesday, December 4, 2024, at 9:35 a.m.
Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in Third Harmonic Bio, Inc. (THRD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Third Harmonic Bio to Participate in Upcoming Investor Conferences in November
SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that management will participate in the following upcoming conferences:
Third Harmonic Bio Announces Third Quarter 2024 Financial Results
THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, today announced financial results for the third quarter September 30, 2024. “As the Phase 1 clinical trial of our development candidate THB335 continues toward an anticipated data readout in the first quarter of 2025, we are also making excellent progress in preparing to move efficiently into a Phase 2 clinical trial in chronic spontaneous urticaria,” said Natalie Holles, Chief Executive Officer at Third Harmonic Bio.
Third Harmonic Bio to Participate in Upcoming Investor Conferences in September
SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in fireside chats at the following upcoming conferences:
Third Harmonic Bio to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the following upcoming conferences:
Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $255.3 million as of June 30, 2024 SAN FRANCISCO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, today announced financial results for the second quarter June 30, 2024, along with business updates. “We are making excellent progress in our Phase 1 SAD/MAD clinical trial of THB335 and now expect to report clinical results during the first quarter of 2025,” said Natalie Holles, Chief Executive Officer at Third Harmonic Bio.
Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 7:30 a.m. ET.
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H'25 Strengthened leadership team with the appointment of Christopher J. Dinsmore, Ph.D.
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors.
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
U.S. IND filed for THB335 with anticipated clinical trial start during 2Q'24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023. “Our team's execution continues to be outstanding, with the filing of our U.S. IND for THB335 ahead of our internal timelines for submission,” said Natalie Holles, Chief Executive Officer of Third Harmonic Bio.
Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference
SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 1:30 p.m. ET.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Third Harmonic Bio, Inc. (NASDAQ: THRD)
NEW YORK , Feb. 22, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Third Harmonic Bio, Inc. (NASDAQ: THRD) on behalf of the company's shareholders. The investigation seeks to determine whether Third Harmonic Bio's directors breached their fiduciary duties in connection with recent corporate actions.
Third Harmonic Bio Announces Leadership Changes
SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the transition of Adrian S. Ray, Ph.D., from Chief Scientific Officer to Scientific Advisor, effective November 1, 2023. In his new role, Dr. Ray will continue support the company's Investigational New Drug (IND) application for THB335, which is expected to be filed during the first half of 2024. Additionally, the company announced that Robert Ho, Chief Financial Officer, will depart the organization on November 10, 2023. The company has initiated executive searches for their successors.
Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference
SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023, from 7:30-7:55 a.m. ET.
Third Harmonic Bio Announces Second Quarter 2023 Financial Results
Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution, and physicochemical profile
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Third Harmonic Bio, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK , Aug. 1, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Third Harmonic Bio, Inc. (NASDAQ: THRD). If you are a shareholder of Third Harmonic Bio, Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: https://pjlfirm.com/third-harmonic-bio-inc/ You may also contact Robert H.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for THRD.